Wo wurde mein verschreibungspflichtiges Generikum hergestellt? – Rx-Inspektor

We’ve launched a first-of-its-kind tool to help you find out where your generic drugs come from and see the track records of the factories that made them.

Even though generic drugs account for 90% of prescriptions dispensed in the U.S., the FDA provides little information about them. It’s scattered across different websites with no easy way to link drugs to their manufacturers, factory locations, and regulatory histories. 

Over many months, our journalists connected that data. In one case, ProPublica had to sue the FDA in federal court and received a partial list of factory locations. 

You can use this app to connect your own medication to the manufacturer that made it, to the specific factory where it was made, and to any FDA inspection reports and serious compliance violations linked to that facility that ProPublica has obtained.

**Check out our Rx Inspector tool:** [https://projects.propublica.org/rx-inspector/](https://projects.propublica.org/rx-inspector/) 

Keep in mind that if you turn up a troubling inspection report, it doesn’t necessarily mean that your drug is compromised. Doctors and pharmacists advise that you not stop taking your medications. Instead, you should talk to your health care provider about any concerns.

**If you’d like to learn how we put this together, read our methodology:** [https://www.propublica.org/article/rx-inspector-fda-generic-drug-tool-methodology](https://www.propublica.org/article/rx-inspector-fda-generic-drug-tool-methodology)

You can read our series on the FDA’s dangerous gamble on America’s drugs: [https://www.propublica.org/series/rx-roulette](https://www.propublica.org/series/rx-roulette) 

*We want to know how you’re using Rx Inspector and what you learn. Send us an email at* [*fda@propublica.org*](mailto:fda@propublica.org) *to tell us what you discover.* 

ProPublica described the app and the methodology used to build it to the FDA, which did not comment. The agency previously told ProPublica that it doesn’t reveal where drugs are made on inspection reports to protect what it deemed confidential commercial information.